Practical use of ANTICOAGULANTS to manage patients with ATRIAL FIBRILLATION

Preventing Thrombosis, Minimizing Bleeding, and Exploring Reversal Agents

PROGRAM SYLLABUS

Presented by

SPEAKER NAME, MD

Hospital Name

Date

Jointly provided by **Potomac Center for Medical Education** and **Rockpointe**

This activity is supported by an educational grant from Daiichi Sankyo, Inc.

CONTENTS

ADDITIONAL PACKET CONTENTS

PROGRAM OVERVIEW/STATEMENT OF NEED

The Potomac Center for Medical Education and Rockpointe welcome you to **Practical Use of Anticoagulants to Manage Patients with Atrial Fibrillation: *Preventing Thrombosis, Minimizing Bleeding, and Exploring Reversal Agents,*** a CME-certified Grand Rounds program designed to give medical professionals the latest news and information on the management of atrial fibrillation (AFib) patients.

AFib increases the risk of ischemic stroke by an average of 5-fold, with the elderly and certain other individuals being at much higher risk. While much of this risk is preventable with the use of an oral anticoagulant, such as warfarin, these agents remain considerably underused. Of patients with known AFib who experienced ischemic stroke, 90% were not appropriately anticoagulated with an oral vitamin K antagonist (such as warfarin) at the time of their first ischemic stroke, and one-third were not taking any anticoagulant/antithrombotic medications at all. Of those admitted with a first ischemic stroke who had known pre-existing AFib, 60% were not taking warfarin prior to admission.

More than 90% of surveyed physicians who treat patients with AFib and stroke acknowledged that traditional anticoagulant therapy is largely underused due to concerns about a narrow therapeutic window and the need to continuously balance protection against thromboembolic events and severe bleeding. This illustrates the need to explore other novel antithrombotic options to ensure that the right drug is prescribed at the right dose for the right patient.

Practical Use of Anticoagulants to Manage Patients with Atrial Fibrillation is an important new grand rounds program that addresses these issues and provides strategies to overcome treatment obstacles.

TARGET AUDIENCE

This CME-certified initiative is intended for general practitioners and other health care providers who are involved in the management of hospitalized patients and out-patients with atrial fibrillation.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

- Identify AFib patients who are at risk for developing ischemic stroke and comply with treatment guidelines for their management
- Evaluate options to overcome the limitations of vitamin K antagonists to reduce the risk of new and recurrent strokes
- Individualize antithrombotic treatments to find the right drug at the right dose for the right patient

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 *AMA PRA Category 1 credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SPECIAL SERVICES

Event staff will be glad to assist you with any special needs.

FEE AND RECEIVING CME CREDIT

There is no fee for this educational activity. To receive CME credit the participant must:

- Participate in this one-hour-long program in its entirety;
- Sign in / sign out on the sheet provided by the host coordinator;
- Complete the evaluation forms;
- Return the evaluation forms to the host coordinator.

DISCLOSURE/CONFLICT OF INTEREST STATEMENT

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

DISCLOSURES

Faculty Speaker

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Faculty Speaker, MD: *Consultant:* Pharma Name; *Clinical Investigator:* Pharma Name

Steering Committee

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Robert P. Giugliano, MD, SM, FACC, FAHA: *Consultant:* Amarin, Amgen, CVS Caremark, Daiichi-Sankyo, GlaxoSmithKline, Lexicon, Merck, Pfizer, Portola, St. Jude, Stealth Peptides; *Research:* Amgen, Merck; *Speaker:* Amgen, Daiichi-Sankyo, Merck

Christian T. Ruff, MD: *Advisory Board:* Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Portola; *Consultant:* Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Portola; *Research:* Daiichi-Sankyo

Non-faculty Content Contributors

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Blair St. Amand; Jay Katz, CHCP; Ashley Marostica, RN, MSN:
Nothing to disclose

FDA DISCLOSURE

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

STEERING COMMITTEE

ROBERT P. GIUGLIANO, MD, SM, FACC, FAHA
Senior Investigator, TIMI Study Group
Associate Physician, Cardiovascular Medicine
Brigham and Women's Hospital
Associate Professor, Harvard Medical School
Boston, MA

Robert P. Giugliano, MD, SM, FACC, FAHA is an Associate Physician in the Cardiovascular Division at the Brigham and Women's Hospital and an Associate Professor of Medicine at Harvard Medical School. He graduated Summa Cum Laude and Phi Beta Kappa (junior year) majoring in mathematics at Dartmouth College in 1985, and received his medical degree at Harvard Medical School in 1989. Dr. Giugliano completed his internship, residency, and chief residency in Los Angeles at Cedars-Sinai Medical Center, an affiliate hospital of UCLA and then returned to Boston as a cardiology fellow at the Massachusetts General Hospital.

In 1996, Dr. Giugliano joined the Brigham and Women's Hospital as a Research Fellow in Medicine working with the Thrombolysis in Myocardial Infarction (TIMI) Study Group under the direction of Eugene Braunwald, and completed a Masters of Science in epidemiology at the Harvard School of Public Health. In 1997, he joined the faculty in the Cardiovascular Division of the Brigham and Women's Hospital and has served as the Principal Investigator for 9 multicenter clinical trials as part of the TIMI Study Group, where he is now a Senior Investigator.

His areas of research include novel antithrombotic and fibrinolytic agents for acute coronary syndromes (ACS), lipid-lowering therapies, and the assessment of outcomes in patients with ACS. He has authored more than 100 articles, 25 editorials/book chapters, and given hundreds of lectures nationally and internationally. Among numerous trials (AVANTE-GARDE-TIMI 43, PROVE IT-TIMI 22, A2Z, and TIMI 11b studies), Dr. Giugliano is the principal TIMI investigator for the EARLY ACS trial investigating early use of eptifibatide in high-risk nSTE-ACS. He also continues to participate in research projects with the Massachusetts General Hospital Unstable Angina/Myocardial Infarction Research Group and the MGH Coronary Clinical Trials Group. Dr. Giugliano is an active participant in the Cardiovascular Medicine Division, attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and also sees patients in a busy growing outpatient practice.

STEERING COMMITTEE



CHRISTIAN T. RUFF, MD
Investigator, TIMI Study Group
Associate Physician, Cardiovascular Medicine Division
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Christian T. Ruff, MD is currently an Associate Physician in the Cardiovascular Division at Brigham and Women's Hospital in Boston, MA and an Assistant Professor of Medicine at Harvard Medical School.

Dr. Ruff graduated Magna Cum Laude from Harvard University with a degree in neurobiology, earned his medical degree with Alpha Omega Alpha honors at the Johns Hopkins University School of Medicine, and his Masters of Public Health at the Harvard School of Public Health. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women's Hospital.

An investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Dr. Ruff serves as the Director of the Pharmacogenetics Core Laboratory and the Assistant Director of the Clinical Events Committee. He has led a broad array of projects, ranging from investigator-initiated studies of biomarkers and genetic variants to large clinical trials, including as lead co-investigator for the ENGAGE AF-TIMI 48 study evaluating the factor Xa inhibitor, edoxaban, for the prevention of thromboembolism in patients with atrial fibrillation.

Dr. Ruff has specific expertise in atrial fibrillation, both risk stratification and implementation of antithrombotic therapy for stroke prevention, as well as the treatment and prevention of venous thromboembolism. He has been selected to serve as Chairman for the Stroke Prevention in Atrial Fibrillation Consensus Initiative for the North American Thrombosis Forum. He also has an interest in developing innovative computational and bioinformatic strategies to identify important relationships across genes, proteins, and compounds. He has given more than a hundred lectures nationally and internationally, as well as authored many scholarly articles, editorials, reviews, and book chapters.

FACULTY



SPEAKER'S NAME, DEGREES
Title
Affiliation
City, STATE

Speaker's biography goes here.